Last updated: August 27, 2026
Ketorolac is a mature, low-cost NSAID with limited opportunity for a new active-ingredient patent. Commercial value is concentrated in excipient-enabled differentiation: preservative-free ophthalmic products, reduced-irritation nasal delivery, unit-dose packaging, improved injection tolerability, and patient-specific oral dosage forms. The strongest opportunities are formulation and device combinations that improve local tolerability, dosing convenience, or supply reliability without increasing systemic NSAID exposure.
What ketorolac products are commercially available?
Ketorolac is marketed primarily as ketorolac tromethamine in ophthalmic, nasal, injectable, and oral dosage forms. U.S. products include generic equivalents and branded or formerly branded delivery systems such as Acular, Acuvail, and Sprix.
| Dosage form |
Typical strength |
Main use |
Commercial differentiation |
| Ophthalmic solution |
0.4% or 0.5% |
Postoperative ocular inflammation and pain; allergic conjunctivitis |
Preservative level, concentration, bottle or unit-dose format |
| Ophthalmic single-dose solution |
0.45% |
Postoperative ocular pain and inflammation |
Preservative-free, lower dosing frequency |
| Nasal spray |
15.75 mg per spray |
Short-term moderate-to-moderately severe acute pain |
Nonoral systemic delivery and metered-dose device |
| Injection |
15 mg/mL or 30 mg/mL |
Short-term acute pain |
Intramuscular or intravenous administration; vial and ampule formats |
| Oral tablet |
Usually 10 mg |
Short-term acute pain |
Low-cost generic tablet; limited formulation differentiation |
The FDA limits ketorolac use because of gastrointestinal, renal, bleeding, and cardiovascular risks. Systemic ketorolac treatment is generally restricted to short-term use, with total therapy not exceeding five days in adults according to FDA labeling.[1,2]
Which excipients are used in ketorolac formulations?
The excipient profile depends heavily on the route of administration. Ophthalmic and nasal products offer the greatest formulation complexity because excipients affect irritation, absorption, sterility, preservative exposure, and device performance.
Ophthalmic excipients
Conventional ketorolac ophthalmic solutions commonly contain:
- Benzalkonium chloride as a preservative
- Sodium chloride for tonicity
- Edetate disodium as a chelating agent
- Povidone or another viscosity-modifying polymer
- Octoxynol-type surfactants in certain products
- Tromethamine or phosphate buffers
- Hydrochloric acid or sodium hydroxide for pH adjustment
- Purified water
The principal formulation challenge is balancing solubility with ocular comfort. Ketorolac tromethamine is water soluble, but the final product must maintain a physiologically acceptable pH and osmolality while limiting stinging and epithelial toxicity.
Acuvail uses a preservative-free, single-dose presentation of ketorolac tromethamine ophthalmic solution 0.45%. The product uses a vehicle that includes carboxymethylcellulose sodium and other buffering and tonicity-adjusting ingredients.[3] This approach supports premium positioning based on preservative avoidance and reduced dosing frequency.
Acular and generic ketorolac ophthalmic solutions generally use multidose bottles with benzalkonium chloride. Benzalkonium chloride can damage the ocular surface with repeated exposure, particularly in patients with dry eye, epithelial compromise, or prolonged treatment. That creates a commercial opening for preservative-free multidose systems, although the device and microbiological-control package must support the claim.
Nasal spray excipients
Sprix, the principal U.S. ketorolac nasal product, contains ketorolac tromethamine in a metered-dose nasal spray. The formulation includes benzalkonium chloride, edetate disodium, sodium chloride, phosphate buffer components, pH adjusters, and water.[4]
For nasal delivery, excipient selection affects:
- Spray plume and droplet-size distribution
- Nasal residence time
- Mucosal irritation
- Dose uniformity across container life
- Microbial preservation
- Absorption variability caused by congestion or mucociliary clearance
Nasal ketorolac has a distinct commercial position because it avoids oral administration while retaining systemic analgesic exposure. Its main limitations are local irritation, short approved treatment duration, device complexity, and competition from injectable and oral NSAIDs.
Injectable excipients
Ketorolac injection products generally use a relatively simple aqueous vehicle containing sodium chloride, water for injection, and pH-adjusting agents. Some presentations contain alcohol or other product-specific ingredients. Multidose products may require antimicrobial preservatives, while single-dose vials and ampules can avoid those excipients.[5]
Injectable opportunities are less dependent on novel chemistry and more dependent on:
- Ready-to-administer packaging
- Low-particulate manufacturing
- Reduced container breakage
- Prefilled syringes
- Hospital inventory efficiency
- Compatibility with infusion systems
- Concentration flexibility for renal-risk and geriatric populations
Oral tablet excipients
Generic ketorolac tablets commonly use standard solid-dose excipients such as microcrystalline cellulose, lactose or another diluent, colloidal silicon dioxide, croscarmellose sodium, povidone, and magnesium stearate. The exact composition varies by manufacturer and strength.[6]
Oral ketorolac has limited premium potential because the molecule is old, the dose is standardized, and the five-day treatment restriction limits recurring use. Excipient innovation could still support orally disintegrating tablets, smaller tablets, lactose-free products, or low-swallowing-burden formulations. These products would need to demonstrate reliable dose delivery without increasing rapid systemic exposure or adverse-event risk.
What excipient strategies offer the strongest commercial opportunities?
1. Preservative-free ophthalmic ketorolac
Preservative-free ophthalmic ketorolac is the clearest formulation opportunity. A successful product could target:
- Cataract and refractive surgery patients
- Patients with dry-eye disease
- Patients receiving multiple chronic eye drops
- Ocular surface disease clinics
- Preservative-sensitive patients
- Surgical centers seeking unit-dose products
The most practical presentations are single-dose vials, blow-fill-seal units, or validated preservative-free multidose containers. The commercial tradeoff is higher packaging cost and greater microbiological-control burden.
A new formulation could use a low-irritation buffer, a mucoadhesive polymer, or a surface-protective excipient. Claims would need to remain within the permitted ketorolac indication and avoid implying superior clinical outcomes unless supported by comparative trials.
2. Lower-irritation nasal ketorolac
Nasal ketorolac has higher excipient and device leverage than tablets or injections. Opportunities include:
- Lower preservative concentration
- Preservative-free unit-dose nasal delivery
- Reduced stinging through pH and osmolality optimization
- Improved plume geometry
- More reliable dosing in congested nasal passages
- Smaller portable devices
- Combination packaging for perioperative discharge
The main regulatory issue is that changing the nasal vehicle can alter absorption and exposure. A formulation that reduces irritation but changes pharmacokinetics may require comparative clinical or pharmacokinetic evidence rather than a simple pharmaceutical-equivalence approach.
3. Unit-dose injectable products
Hospital buyers may value unit-dose ketorolac products that reduce preparation time and medication errors. Potential formats include:
- Ready-to-administer syringes
- Polymer ampules with improved break resistance
- Low-volume vials
- Concentration-specific products for emergency departments
- Dual-language or barcode-enabled packaging
- Preservative-free products for high-risk populations
These features may be protectable through device, container, or manufacturing claims rather than conventional composition claims.
4. Oral products for adherence and swallowing
An orally disintegrating tablet or mini-tablet could target postoperative patients with nausea or swallowing difficulty. The formulation must control:
- Rapid disintegration without excessive bitterness
- Dose uniformity
- Moisture sensitivity
- Mechanical strength
- Absorption profile
- Patient exposure to sweeteners and flavoring agents
This segment is commercially narrower than ophthalmic products. Ketorolac’s short treatment period limits the value of adherence improvements.
What patents protect ketorolac formulations?
The active ketorolac molecule and core pharmaceutical uses are mature. Most basic composition-of-matter and early use protection has expired or is commercially irrelevant in the United States. Current value is more likely to arise from formulation, delivery-device, packaging, manufacturing, and method-of-use claims.
| IP category |
Likely protection scope |
Commercial relevance |
| Active ingredient |
Ketorolac or ketorolac tromethamine |
Generally exhausted for U.S. generic competition |
| Ophthalmic composition |
Concentration, pH, polymer, preservative, tonicity, stability |
Moderate |
| Preservative-free delivery |
Unit-dose container or multidose valve system |
Moderate to strong if technically specific |
| Nasal formulation |
Vehicle, absorption profile, spray characteristics |
Moderate |
| Delivery device |
Metered-dose pump, actuator, container closure |
Moderate |
| Manufacturing process |
Sterile filtration, aseptic filling, crystallization, impurity control |
Moderate |
| Method of use |
Dosing schedule, surgical use, patient subgroup |
Usually narrow and vulnerable to design-around |
| Packaging |
Unit-dose, prefilled syringe, tamper evidence |
Usually narrow |
The Orange Book should be reviewed at the product level because listed patents can differ among branded products, dosage forms, and approved indications.[7] FDA-approved generic ketorolac products may have no listed patents or may rely on certifications to patents listed for the reference product, depending on the product and approval history.
When does ketorolac lose exclusivity?
Ketorolac has already lost practical U.S. market exclusivity for its core active ingredient and conventional dosage forms. Generic oral, injectable, and ophthalmic products are widely available. The remaining exclusivity value is product-specific and may attach to a branded formulation, delivery device, or approved indication.
FDA regulatory exclusivity can still arise in limited circumstances, but ketorolac does not have the profile of a recently approved chemical entity. The principal competitive barriers are therefore:
- Abbreviated New Drug Application requirements.
- Pharmaceutical equivalence and bioequivalence.
- Sterile manufacturing capacity.
- Device qualification for nasal and ophthalmic products.
- Stability data.
- Supply-chain reliability.
- Hospital or ophthalmology purchasing contracts.
There is no biosimilar pathway for ketorolac. It is a small-molecule drug, so competitive products use the generic-drug framework rather than the Biologics Price Competition and Innovation Act pathway.[8]
What Paragraph IV challenges and litigation affect ketorolac?
Paragraph IV litigation is most relevant to any remaining branded ketorolac product with Orange Book-listed patents. Generic applicants may certify that listed patents are invalid, unenforceable, or will not be infringed. A Paragraph IV certification can trigger a 45-day period for the patent holder to file an infringement action and may create a 30-month stay of approval under the Hatch-Waxman framework, subject to statutory exceptions.[9]
For mature ketorolac products, litigation risk is generally lower for conventional oral and injectable products because multiple generic manufacturers already compete. Risk can be higher for:
- Preservative-free ophthalmic products
- Metered nasal sprays
- Device-dependent presentations
- New concentration or dosing regimens
- Formulations with narrow pharmaceutical-equivalence requirements
No settlement terms should be inferred from product availability alone. A commercial launch may reflect patent expiry, a noninfringement position, a license, or a settlement. Current litigation and settlement analysis requires review of FDA patent listings, Abbreviated New Drug Application certifications, PACER filings, and product-specific agreements.
How strong is the ketorolac patent estate?
The core ketorolac estate is weak because the active ingredient is mature and generic competition is established. A new estate could still be commercially meaningful if it combines:
- A clinically useful formulation change
- A measurable tolerability benefit
- A device that is difficult to substitute
- Manufacturing know-how not readily disclosed in the patent
- Regulatory exclusivity or market access
- Strong supply and contracting execution
Composition claims covering only routine excipients are vulnerable to obviousness challenges. Stronger claims would link the excipient system to a specific technical result, such as improved stability, reduced ocular-surface toxicity, controlled nasal absorption, or uniform delivered dose.
What FDA regulatory pathway applies to new ketorolac products?
A conventional generic product typically proceeds through an ANDA by demonstrating pharmaceutical equivalence and bioequivalence to the reference-listed drug. A materially different formulation, route, strength, or device may require a 505(b)(2) application.[10]
| Product concept |
Likely U.S. pathway |
| Same strength and route as approved generic |
ANDA |
| New preservative-free ophthalmic vehicle |
ANDA or 505(b)(2), depending on formulation and reference product |
| New nasal device or altered spray characteristics |
Potentially 505(b)(2) |
| New strength or dosing schedule |
Often 505(b)(2) |
| New indication |
505(b)(2) or supplemental application |
| New combination product |
505(b)(2), with combination-product review if applicable |
The regulatory burden rises when excipients alter exposure, local tolerability, residence time, or delivered dose. The commercial case must account for comparative clinical studies, device human-factors work, extractables and leachables, container-closure testing, and sterile-process validation.
Which companies are competing in ketorolac?
Competition includes generic manufacturers, branded ophthalmic suppliers, specialty injectable companies, and firms with nasal-delivery capabilities. Major competitive variables are price, shortage history, sterile capacity, wholesaler access, and ophthalmology or hospital sales coverage.
The most defensible commercial segments are not broad generic tablets. They are:
- Preservative-free ophthalmic ketorolac
- Premium postoperative eye-drop packaging
- Nasal ketorolac with improved tolerability
- Ready-to-administer hospital injection
- Contract manufacturing for sterile ketorolac products
- Regional licensing of ophthalmic or nasal delivery technology
Public companies generally do not report ketorolac revenue as a separate line item. Revenue exposure must therefore be estimated from product-level sales, contract awards, market-share data, and segment disclosures rather than company-wide pharmaceutical revenue.
What licensing opportunities exist for ketorolac?
Potential licensing structures include:
- In-licensing of a preservative-free ophthalmic platform
- Regional rights to a nasal spray device
- Contract development and manufacturing agreements
- Hospital-channel distribution rights
- Co-development of prefilled injectable products
- Licensing of sterile blow-fill-seal packaging
- Supply agreements for ketorolac tromethamine API or finished dosage form
A license is most valuable when it transfers a difficult-to-replicate capability, such as a validated ophthalmic container, a nasal pump with consistent dose delivery, or a sterile filling process. A license covering only routine excipients is less likely to support durable pricing.
What generic launch risks exist for new ketorolac products?
Generic launch risk depends on the product category.
| Product category |
Generic entry risk |
Principal barrier |
| 10 mg oral tablet |
Very high |
Minimal formulation differentiation |
| Standard injection |
High |
Sterile manufacturing and contracts |
| Conventional ophthalmic solution |
High to moderate |
Established generic technology |
| Preservative-free ophthalmic product |
Moderate |
Packaging, sterility, stability, device |
| Nasal spray |
Moderate |
Device, PK, local tolerability, manufacturing |
| Prefilled injection |
Moderate |
Container system and hospital adoption |
| Novel local-delivery product |
Lower initially |
Clinical and regulatory requirements |
Geographic coverage is strongest in the United States, Europe, Canada, and other markets with mature generic competition. Emerging markets may offer larger whitespace for unit-dose ophthalmic and nasal products, but regulatory requirements, pricing controls, local manufacturing rules, and tender systems can reduce margins.
Key Takeaways
- Ketorolac’s core active-ingredient protection has expired, and conventional dosage forms face intense generic competition.
- Preservative-free ophthalmic formulations offer the strongest excipient-led opportunity.
- Nasal delivery offers the highest combination of formulation, device, and packaging differentiation.
- Injectable products can gain value through prefilled, ready-to-administer, and preservative-free formats.
- Routine excipient substitutions are unlikely to support strong patent protection without a demonstrated technical effect.
- Ketorolac has no biosimilar risk because it is a small-molecule NSAID.
- ANDA is the likely pathway for equivalent products; materially changed formulations and devices may require 505(b)(2) development.
- Commercial value depends more on sterile manufacturing, device reliability, contracting, and regulatory execution than on the ketorolac molecule itself.
FAQs
Is preservative-free ketorolac ophthalmic commercially attractive?
Yes. It can target patients with ocular-surface disease, repeated eye-drop exposure, and preservative sensitivity. Unit-dose packaging and sterile manufacturing costs remain the main constraints.
Can a new excipient create patent protection for ketorolac?
Yes, but a patent is stronger when it claims a defined composition linked to an unexpected stability, tolerability, absorption, or delivered-dose result. A routine excipient substitution is more vulnerable to invalidity challenges.
Is ketorolac nasal spray safer than oral ketorolac?
Nasal administration avoids swallowing but still produces systemic ketorolac exposure. Route of administration does not remove the NSAID risks that drive the short treatment limit and contraindications in FDA labeling.[4]
Are ketorolac products eligible for 180-day generic exclusivity?
An ANDA applicant may qualify for 180-day exclusivity if it is the first applicant with a valid Paragraph IV certification and satisfies the statutory requirements. Eligibility is product-specific and depends on the reference product, patent listings, and FDA approval history.[9]
What is the best ketorolac lifecycle-management strategy?
The strongest strategy is a differentiated sterile product: preservative-free ophthalmic delivery, a more tolerable nasal spray, or a ready-to-administer injectable system supported by device, formulation, manufacturing, and packaging claims.
References
- U.S. Food and Drug Administration. (2024). Ketorolac tromethamine injection prescribing information.
- U.S. Food and Drug Administration. (2024). Ketorolac tromethamine tablets prescribing information.
- U.S. Food and Drug Administration. (2024). Acuvail prescribing information.
- U.S. Food and Drug Administration. (2024). Sprix prescribing information.
- DailyMed. (2024). Ketorolac tromethamine injection product labeling. National Library of Medicine.
- DailyMed. (2024). Ketorolac tromethamine tablet product labeling. National Library of Medicine.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biologic products.
- U.S. Code, 21 U.S.C. § 355(j). Abbreviated applications for new drugs.
- U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2).
